F18 Fluciclovine and PSMA-ligand PET offer a robust solution for the evaluation of recurrent prostate cancer, and in the case of PSMA, they localize disease and guide treatment in intermediate- to high-risk patients. Here, FOLH1 is linked to prostate cancer.